Inovio amends bylaws to establish Lead Independent Director role
Inovio Pharmaceuticals amended its bylaws on May 19, 2026 to formalize governance structure including a Lead Independent Director position and clarified chairman duties. The changes enhance board independence and oversight mechanisms, particularly when the CEO serves as chairman.
View filing at SEC.gov →